Prognostic value of the preoperative lymphocyte-to-monocyte ratio for survival after lung cancer surgery
verfasst von:
Ricard Ramos, Ivan Macía, Arturo Navarro-Martin, Carlos Déniz, Francisco Rivas, Anna Ureña, Cristina Masuet-Aumatell, Camilo Moreno, Ernest Nadal, Ignacio Escobar
The aim of this study was to assess the effect of the lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on overall survival and disease-free survival in patients with lung cancer treated with radical surgery.
Methods
We performed a retrospective review of patients with lung cancer who prospectively underwent radical resection between 2004 and 2012. Blood samples were taken as part of the preoperative workup. The inflammatory markers studied were absolute values of lymphocytes, monocytes, neutrophils and platelets, with subsequent calculation of ratios. Median follow-up was 52 months.
Results
Two hundred and sixty-eight patients underwent surgery, of whom 218 (81.3%) were men. Mean age was 62.9 ± 8.7 years. A lymphocyte-to-monocyte ratio ≥ 2.5 was independently associated with longer disease-free survival (hazard ratio [HR] 0.476 (0.307–0.738), p = 0.001) and longer overall survival (HR, 0.546; 95% CI: 0.352–0.846; p = 0.007), in models adjusted for age, sex, stage, and type of resection. No other systemic inflammatory marker showed a significant association.
Conclusion
Preoperative LMR is an independent prognostic factor of overall survival and recurrence-free survival in patients with surgically-resected early stage lung cancer.
Hinweise
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
LMR
Lymphocyte-to-monocyte ratio
NLR
Neutrophil-to-lymphocyte ratio
PLR
Platelet-to-lymphocyte ratio
OS
Overall survival
DFS
Disease-free survival
HR
Hazard ratio
NSCLC
Non-small cell lung cancer
CT
Computed tomography
PET-CT
Positron-emission tomography/computed tomography
ROC
Receiver operating characteristics
Background
Lung cancer causes the most cancer-related deaths worldwide. Increasing knowledge of tumour biology and multimodal treatments have helped improve treatment, and several prognostic factors exist, but overall survival remains poor, except in stage I, for which survival ranges between 60 and 80% [1, 2].
Prognostic factors related not to the tumour itself but to the patient’s general health status have been studied, including nutritional status and inflammatory status. Nutritional status is a prognostic factor in patients with lung cancer [3, 4], and our group has confirmed that nutritional status affects survival and postoperative outcomes in patients with lung cancer who undergo surgical resection [5].
Anzeige
Another prognostic factor that has been associated with survival and complications is inflammatory status. Multiple parameters can be used to determine the inflammatory status of a patient with cancer, but blood markers that are often used in preoperative assessment due to being simple to obtain are C reactive protein, absolute values of neutrophils, lymphocytes, monocytes and platelets, and the ratios of neutrophils to lymphocytes, platelets to lymphocytes and lymphocytes to monocytes. Certain levels of these parameters are associated with better or worse survival in various cancers, including lung cancer [6, 7].
The European Lung Cancer Working Group confirmed that patients with a high neutrophil count had worse survival [8]. Likewise, a high neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are markers of worse prognosis in patients with cancer in general and particularly in lung cancer [9, 10]; however, within the inflammatory response, lymphocytes and monocytes both play an important role in postoperative outcomes following lung cancer resection [11, 12].
In this study, we assessed the effect of these systemic inflammatory markers on overall survival (OS) and disease-free survival (DFS) in patients with non-small cell lung cancer (NSCLC) who underwent radical resection with follow-up of at least 5 years.
Methods
Study population
We retrospectively reviewed a cohort of 653 patients who were treated with radical lung resection between January 2004 and December 2012. Patients with a history of systemic inflammatory disease, concomitant active infection, neoadjuvant treatment, preoperative stage ≥ T3, preoperative stage ≥ N1, patients lost to follow-up, or those for whom preoperative blood tests were not available were excluded (Fig. 1). Finally, we included 268 patients diagnosed with early clinical stage non-small cell lung cancer who underwent anatomic pulmonary resection with systematic lymph node dissection.
Fig. 1
Flow chart of patient selection
×
Anzeige
All patients underwent the same preoperative workup which included physical examination, full blood count and renal function tests, bronchoscopy, pulmonary function tests with diffusion studies, computed tomography (CT) and positron-emission tomography/computed tomography (PET-CT). All patients signed an informed consent form and the study was approved by the Institutional Review Board.
Study variables
The variables studied were age, sex, comorbidities (smoking, diabetes mellitus, ischaemic heart disease, chronic obstructive pulmonary disease, and hypertension), type of surgery performed, pathological stage, tumour histology, disease-free survival and overall survival. The study aims did not include the association between these markers and postoperative complications.
The lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were calculated from the absolute neutrophil, platelet, monocyte and lymphocyte counts from routine preoperative testing performed 1–2 weeks before surgery at the same hospital.
Follow-up
Routine follow-up was carried out at 1 month after surgery and included a full panel of blood tests and chest X-ray, then every 6 months with CT chest for the first 3 years, with annual checks thereafter, as per hospital protocol. If recurrence was suspected after surgery, the relevant tests, eg PET-CT, MRI brain, were requested according to the clinical scenario. Recurrences were classified as locoregional or distant metastases based on imaging. Locoregional recurrence was defined as recurrence in mediastinal or hilar lymph nodes or ipsilateral lung. Other recurrences were defined as distant metastases. All patients were seen by specialists and discussed by the multidisciplinary team to decide on treatment planning. Diagnosis of recurrence or distant metastases was evaluated and confirmed in the multidisciplinary unit.
Statistical analysis
A descriptive analysis of the sample was performed as frequency and percentage for qualitative variables, and mean and standard deviation for quantitative variables if they followed a normal distribution (Kolmogorov–Smirnov, p value > 0.05), or median and interquartile range if not. Subsequently, Kaplan–Meier survival analysis was performed, and variables that were clinically relevant and statistically significant (Log rank p value < 0.05) and that did not show interaction between them were included in Cox regression. A receiver operating characteristics (ROC) analysis was performed to calculate the NLR, PLR, and LMR values that would have the greatest sensitivity and specificity. The statistical software SPSS v 16.0 was used.
Results
Two hundred and sixty-eight patients were included in the study, of whom 218 (81.3%) were men. The mean age was 62.9 ± 8.7 years. Clinical, surgical, and pathological features and blood values of the study population are shown in Table 1. Twenty-five patients (9.2%) received tumour-specific adjuvant treatment. The median follow-up time was 52 months. One hundred patients (37.3%) developed recurrence, of whom 74 (27.6%) had distant metastases and 26 (9.7%) had locoregional recurrence. Twelve patients (4.5%) developed second primary lung tumours and underwent new radical surgery. One hundred and fifty-nine (57.3%) patients were still alive at the end of follow-up; 109 (42.7%) patients died.
Table 1
Clinical, surgical, pathological and inflammatory parameters for the study population
Following ROC analysis, the values with the greatest sensitivity and specificity were 2.5 for NLR and LMR and 150 for PLR. Disease-free survival and OS were evaluated after splitting patients according to these proposed maker levels (Table 2). An LMR ≥ 2.5 was a clear prognostic factor for higher overall survival and lower recurrence in patients with surgically-resected lung cancer (p = 0.001) (Figs. 2, 3). On univariate analysis, age, pathological stage and LMR ≥ 2.5 were significantly associated with higher disease-free survival (HR, 0.444; 95% CI 0.289–0.683; p = 0.001). These variables remained statistically significant on multivariate analysis (HR, 0.476; 95% CI 0.307–0.738; p = 0.001; Table 3) after adjusting for age, sex, pathological stage and histology.
Table 2
Distribution of patients according to LMR
Study population, n: 268
LMR < 2.5
LMR ≥ 2.5
No. of patients
47
221
No. of patients who died during the follow-up period
28
81
No. of patients who died or had recurrence during the follow-up period
35
107
LMR lymphocyte-to-monocyte ratio
Fig. 2
Kaplan–Meier analysis of overall survival (OS) based on LMR
Fig. 3
Kaplan–Meier analysis of disease-free survival (DFS) based on LMR
Table 3
Univariate and multivariate analysis of disease-free-survival (DFS)
Covariables
Hazard ratio
95% CI
p value
Univariate analysis
PLR ≥ 150
0.986
0.654–1.488
0.948
NLR ≥ 2.5
1.203
0.821–1.761
0.343
LMR ≥ 2.5
0.444
0.289–0.683
0.001
Age
1.018
0.996–1.040
0.112
Sex (female)
0.970
0.595–1.579
0.901
Pathological stage
0.051*
I
1.000
II
1.686
1.126–2.526
0.011
III
1.793
0.812–3.958
0.148
IV
2.536
0.350–18.380
0.357
Histological type
0.219*
Adenocarcinoma
1.000
Squamous cell carcinoma
0.618
0.384–0.995
0.048
Large cell carcinoma
0.792
0.381–1.646
0.532
Other
0.568
0.138–2.343
0.434
Multivariate analysis
LMR ≥ 2.5
0.476
0.307–0.738
0.001
Age
1.029
1.005–1.054
0.017
Sex
Male
1.000
Female
1.171
0.693–1.977
0.556
Pathological stage
0.027*
I
1.000
II
1.779
1.174–2.695
0.007
III
1.878
0.848–4.162
0.120
IV
3.101
0.406–23.695
0.275
Histological type
0.053*
Adenocarcinoma
1.000
Squamous cell carcinoma
0.527
0.322–0.862
0.011
Large cell carcinoma
0.619
0.294–1.301
0.205
Other
0.541
0.127–2.306
0.407
LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
*Linear trend p value
×
×
Regarding overall survival, univariate analysis showed that age, pathological stage and LMR ≥ 2.5 were associated with better overall survival (HR, 0.488; 95% CI 0.317–0.751; p = 0.001). These variables were also significant on multivariate analysis (HR, 0.546; 95% CI 0.352–0.846; p = 0.007; Table 4) after adjusting for age, sex, pathological stage and histology. NLR and PLR were not found to be prognostic factors for overall survival or disease-free survival.
Table 4
Univariate and multivariate analysis of overall survival
Covariables
Hazard ratio
95% CI
p value
Univariate analysis
PLR ≥ 150
1.151
0.772–1.715
0.494
NLR ≥ 2.5
1.175
0.806–1.714
0.401
LMR ≥ 2.5
0.488
0.317–0.751
0.001
Age
1.037
1.013–1.060
0.002
Sex (female)
0.831
0.481–1.436
0.507
Pathological stage
0.026*
Stage I
1.000
Stage II
1.718
1.148–2.571
0.009
Stage III
1.980
0.975–4.017
0.059
Stage IV
2.296
0.317–16.631
0.411
Histological type
0.999*
Adenocarcinoma
1.000
Squamous cell carcinoma
0.991
0.651–1.509
0.967
Large cell carcinoma
1.041
0.518–2.091
0.909
Other
0.986
0.135–7.190
0.989
Multivariate analysis
LMR ≥ 2.5
0.546
0.352–0.846
0.007
Age
1.041
1.017–1.066
0.001
Sex
Male
1.000
0.966
Female
1.013
0.564–1.819
Pathological stage
0.013*
I
1.000
II
1.783
1.179–2.697
0.006
III
2.144
1.047–4.389
0.037
IV
4.083
0.521–31.995
0.180
Histological type
0.830*
Adenocarcinoma
1.000
Squamous cell carcinoma
0.812
0.525–1.255
0.348
Large cell carcinoma
0.923
0.457–1.864
0.824
Other
0.929
0.122–7.056
0.943
LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
*Linear trend p value
Anzeige
Discussion
The association between inflammation and cancer was first described years ago and has been the subject of much study. O’Callaghan et al. [13] described the role of inflammation in the etiopathogenesis of lung cancer, and multiple studies have confirmed the prognostic value of inflammation in lung cancer outcomes, for both local and advanced disease [10, 14].
Our study included 268 patients who underwent resection and prospective follow-up for at least 5 years, and demonstrates that an LMR ≥ 2.5 is an independent positive prognostic factor for disease-free survival and overall survival. Although this ratio has not been studied extensively in cancer and particularly bronchogenic cancer, our findings are in line with those obtained by other groups. Xia et al. [15], in 439 patients with stage I NSCLC, demonstrated a positive association between LMR and overall survival and a greater risk of distal metastases with lower LMR. However, Asian populations may behave differently from European populations in terms of blood markers, so their results will need to be validated in a Western population.
In 2018, Chen et al. [16] published a series of 577 surgical patients in stage IB NSCLC who had undergone pneumonectomy. They found that LMR and PLR were independent prognostic factors for OS. In our series, LMR was an independent prognostic factor for OS and DFS. However, we did not find a statistically significant association for PLR as a prognostic factor. One explanation could be that the patients requiring pneumonectomy are usually patients with larger tumours or with greater intrapulmonary lymph node involvement, so they are likely to have higher baseline levels of inflammation. In our study only 5.2% of the patients had undergone pneumonectomy, while 100% of those in the study by Chen et al. had undergone pneumonectomy, with pleural invasion in 39% of the cases.
The immunological basis for our findings is that lymphoid cells play a primordial role in the control, proliferation, and migration of tumour cells [17]. In cervical cancer, it has been observed that lymphocytes act as essential components of the immune response, and low levels of lymphocytes in the peripheral blood and tumour stroma lead to a weaker immune response against the cancer cell [18]. In contrast, the presence of high levels of monocytes and their derivatives induces immunosuppression and tumour neoangiogenesis. In addition, intratumour macrophages, derived directly from tissue monocytes, facilitate tumour cell migration by secreting mediators that degrade the extracellular matrix and attract more intratumour monocytes/macrophages, leading to greater tumour aggressiveness both locally and distally [19‐22].
Anzeige
In nonsurgical treatments such as stereotactic radiation therapy, several groups have described the effect of NLR and PLR in terms of local recurrence. Canon et al. [10] found that PLR should be used as a prognostic factor for DFS. In our study, we did not find such an association, but we must bear in mind that the inflammatory status in the nonsurgical population is probably different: although in some cases patients decline surgery, in many cases they are unsuitable for surgery due to comorbidities.
The interaction between nutritional status, systemic inflammatory status and tumour inflammatory status plays a key role in postoperative outcomes and prognosis in patients with lung cancer [23]. This explains why a higher or lower LMR confers better or worse disease prognosis among patients undergoing surgery, who theoretically will have better long-term outcomes.
The present study has the limitations of being a single-centre retrospective study. Also, although the preoperative testing used to obtain the ratios was the same for all patients, the findings have not been validated in an independent cohort. The ideal cut-off point for the ratio is difficult to establish, but according to our results, the value with the greatest sensitivity and specificity was 2.5; values above or below this showed significant differences in overall survival and disease-free survival, in line with other published studies [15‐17, 24, 25].
The number of patients included, more than 200, the consistency of the blood testing method, the follow-up time and the prospective format of data recording make the data presented relevant for future research.
Anzeige
Conclusions
The findings from this study in a cohort of patients who underwent surgery for NSCLC confirm that the lymphocyte-to-monocyte ratio is a convenient preoperative biomarker that could provide valuable information on the probability of recurrence and overall survival in this population.
Acknowledgements
Not applicable.
Ethics approval and consent to participate
All patients signed an informed consent form. The study was approved by the Clinical Research Ethics Committee of Bellvitge University Hospital (CEIC). All methods were carried out in accordance with relevant guidelines and regulations.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Prognostic value of the preoperative lymphocyte-to-monocyte ratio for survival after lung cancer surgery
verfasst von
Ricard Ramos Ivan Macía Arturo Navarro-Martin Carlos Déniz Francisco Rivas Anna Ureña Cristina Masuet-Aumatell Camilo Moreno Ernest Nadal Ignacio Escobar
Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.
Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.
Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.
Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
